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Hypoxic stress, like DNA damage, induces p53 protein accumulation and p53-dependent apoptosis in on-
cogenically transformed cells. Unlike DNA damage, hypoxia does not induce p53-dependent cell cycle arrest, sug-
gesting that p53 activity is differentially regulated by these two stresses. Here we report that hypoxia induces
p53 protein accumulation, but in contrast to DNA damage, hypoxia fails to induce endogenous downstream p53
effector mRNAs and proteins. Hypoxia does not inhibit the induction of p53 target genes by ionizing radiation,
indicating that p53-dependent transactivation requires a DNA damage-inducible signal that is lacking under
hypoxic treatment alone. At the molecular level, DNA damage induces the interaction of p53 with the tran-
scriptional activator p300 as well as with the transcriptional corepressor mSin3A. In contrast, hypoxia pri-
marily induces an interaction of p53 with mSin3A, but not with p300. Pretreatment of cells with an inhibitor
of histone deacetylases that relieves transcriptional repression resulted in a significant reduction of p53-de-
pendent transrepression and hypoxia-induced apoptosis. These results led us to propose a model in which
different cellular pools of p53 can modulate transcriptional activity through interactions with transcriptional
coactivators or corepressors. Genotoxic stress induces both kinds of interactions, whereas stresses that lack a
DNA damage component as exemplified by hypoxia primarily induce interaction with corepressors. However,
inhibition of either type of interaction can result in diminished apoptotic activity.
The critical role of p53 in tumor suppression is underscored
by the findings that the p53 gene is mutated in over 50% of
human cancers (17) and that mice nullizigous for the p53 gene
develop tumors early in their lifetime (10). Two functions of
p53 that have been proposed to be responsible for its role as a
tumor suppressor are the induction of cell cycle arrest in re-
sponse to DNA damage and the induction of apoptosis. Fol-
lowing DNA damage, p53 binds to DNA in a sequence-depen-
dent manner, and through interactions with the transcriptional
coactivator p300 (also called CBP) (4, 27) as well as basal
transcription factors like TFIID (13), it induces the transcrip-
tion of downstream effector genes whose products interact with
and inhibit proteins involved in cell-cycle regulation (for a
review, see 26).
The molecular events that lead to p53-dependent apoptosis
are less clear. p53-dependent transactivation has been report-
ed to induce apoptosis in some experimental systems (9, 53,
55). However, under other conditions it appears that macro-
molecular synthesis is completely dispensable for the induction
of p53-dependent apoptosis (7, 51). Furthermore, expression
of p53 mutants that lack transactivation capability is able to
induce apoptosis in certain cell lines (9, 21, 40), and deletion of
the polyproline-rich domain of p53 which is located between
the transactivation and DNA binding domains of p53 abro-
gates the apoptotic properties of p53 but does not affect DNA
binding, bax induction, or cell cycle inhibition (43). There is
also increasing evidence that p53-dependent transrepression
may also contribute to the induction of apoptosis (35, 36, 39,
41, 50). In addition, the interaction of p53 with two proteins,
XPB and XPD, that are components of the basal transcription
factor TFIIH, has been suggested to be essential for UV-
induced apoptosis of human fibroblasts (52). The consensus
from the above findings is that different mechanisms of p53-
mediated apoptosis may exist which may function coordinately
or independently in different experimental systems depending
on factors such as cell type, type of stress, levels of p53, and
oncogenic activity.
Accumulation of the p53 protein following genotoxic stress
involves posttranscriptional mechanisms such as enhanced
translation of p53 mRNA and decreased proteolytic degrada-
tion of the protein (26, 28, 33). Activation of p53 following
genotoxic damage is achieved by induction of p53 levels and by
modifications of the p53 protein such as phosphorylation and
acetylation (reviewed in references 14 and 38). Phosphoryla-
tion of serines 15 and 20 following genotoxic stress (8, 29,
44–46, 48) has been shown to impair interaction between p53
and Mdm-2, resulting in enhanced p53 accumulation (38, 44,
48), suggesting another means of modulating p53-dependent
apoptosis. p53 is also extensively phosphorylated at other sites
in vitro and in vivo in response to genotoxic damage (reviewed
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in references 14, 29, and 38). Although some of these post-
translational modifications increase the sequence-specific DNA
binding activity of p53 and its transactivation properties in
vitro, the physiological significance of these modifications in
vivo remains to be determined.
Tumor hypoxia develops in most solid tumors as a result of
inefficient vascular development, or abnormal vascular archi-
tecture (6). Previous studies have demonstrated that hypoxia is
an independent prognostic factor of survival independent of
other factors, including tumor grade or treatment modality
(surgery or radiotherapy) (22). In contrast to DNA damage,
hypoxia is a physiological inducer of the p53 tumor suppressor
gene product (15) and can act as a selective pressure during
tumor growth for the elimination of cells with wild-type (wt)
p53 and the clonal expansion of cells with mutant or otherwise
inactive p53 protein (16). This observation provides a possible
explanation for the more aggressive nature of hypoxic tumors
compared to well-oxygenated ones and for the frequent occur-
rence of p53 mutations in advanced stages of tumor develop-
ment.
Little is known about the regulation of p53 function in oxy-
gen-deprived cells and the role of known endogenous down-
stream effectors of p53 in this process. In this study we present
evidence indicating that similar to genotoxic damage, hypoxia
induces p53 protein accumulation and apoptosis. Unlike DNA
damage, hypoxia fails to enhance the transactivation properties
of p53. However, hypoxia does induce p53 transrepression
activity, and inhibition of this activity significantly decreases
p53-dependent apoptosis under hypoxic conditions.
MATERIALS AND METHODS
Cell lines. Human breast carcinoma MCF-7, human colorectal carcinoma
RKO, Epstein-Barr virus-transformed human lymphocytes GM2184B, and HT1299
cell lines were obtained from the American Type Culture Collection (Manassas,
Va.). p531/1 and p53-null mouse embryonic fibroblasts (MEFs) transformed
with E1A and ras (15) were a gift from Scott Lowe (Cold Spring Harbor Labo-
ratory, Cold Spring Harbor, N.Y.).
Hypoxic treatments. Treatment of cells with hypoxia was performed either in
a hypoxic chamber (,0.2% O2) (Sheldon Corp., Cornelius, Oreg.) or in specially
designed aluminum chambers for dose-response experiments (2 to 0.02% O2)
and for experiments in which cells were irradiated under hypoxia.
Determination of apoptotic cells. Cells with apoptotic morphology were iden-
tified by staining with Hoechst dye 33342 (blue) (5 mg/ml) for changes in nuclear
characteristics and with propidium iodide (pink) (5 mg/ml) for loss of membrane
integrity. Apoptotic values were calculated as the percentage of apoptotic cells
relative to the total number of cells in each field (.100 cells) and represent the
average of four randomly selected fields per 60-mm-diameter dish.
Immunoblotting and immunoprecipitation. Primary antibodies used for im-
munoblotting were DO-1 mouse monoclonal for human p53, M-19 rabbit poly-
clonal for human p21, and SMP14 mouse monoclonal for human Mdm-2 (Santa
Cruz Biotechnology, Santa Cruz, Calif.). The anti-mSin3A (K-20) and anti-p300
(N-15) rabbit polyclonal antibodies used for coimmunoprecipitations of p53
protein were purchased from Santa Cruz Biotechnology. For immunoprecipita-
tion and immunoblotting, cell extracts were prepared by lysing 107 to 108 cells in
buffer A, which contained 10 mM Tris (pH. 7.5), 1 mM EDTA, 400 mM NaCl,
10% glycerol, 0.5% NP-40, 5 mM NaF, 0.5 M Na3VO5, 1 mM dithiothreitol
(DTT), and 1 mM phenylmethylsulfonyl fluoride (PMSF). Lysates were incu-
bated on ice for 10 min and then centrifuged at 6,000 3 g to remove cellular
debris. Forty to fifty micrograms of protein was used for Western transfer and
immunoblotting. For immunoprecipitations cell lysates (2 to 4 mg) were mixed
with an equal volume of TEG buffer, which contained 10 mM Tris (pH 7.5),
1 mM EDTA, 20% glycerol, 5 mM NaF, 0.5 mM Na3VO5, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride (PMSF), and 3 mg of polyclonal antibody 1801 and
rocked at 4°C overnight. Antibody-protein complexes were captured by addition
of 40 ml of protein A–G-Plus beads (Santa Cruz Biotechnology) for 2 h. Immu-
noprecipitates were washed three times with buffer B, which contained 0.5 M
Tris (pH 7.9), 250 mM KCl, 0.3% NP-40, 0.1% Triton X-100, 0.01% sodium
dodecyl sulfate, and 1 mM DTT; resuspended in 3X SDS gel loading buffer, and
analyzed on 9% polyacrylamide gels.
Immunofluorescent staining. Immunofluorescent staining of RKO cells was
performed as described by Graeber et al. (15). Cells were placed on Lab-Tek
slides (Nunc, Naperville, Ill.), treated, and then fixed for 5 min with methanol
previously stored at 220°C. After fixation, the slides were incubated for 20 min
with 10% goat serum in phosphate-buffered saline (PBS). The slides were washed
with PBS and then incubated with mouse anti-53 antibody (DO-1 at 1 mg/ml) for
60 min. After another wash, the slides were incubated in fluorescein isothiocya-
nate-conjugated goat anti-mouse immunoglobulin (secondary) antibody (20 mg/
ml; Caltag, South San Francisco, Calif.) for 60 min before a final wash. Coverslips
were then mounted onto the slides, and the slides were photographed at a X600
magnification. As controls, slides that were stained with secondary antibody
alone showed no significant fluorescence. All incubations were done at room
temperature.
RNA isolation, Northern hybridization, and RPA. Total RNA was isolated
from 106 to 107 cells grown in monolayers using a modified guanidine isothio-
cyanate protocol (Trizol reagent; Gibco Life Sciences) according to the manu-
facturer’s protocol. Northern hybridization assays were performed using 20 mg of
total RNA. Radiolabeled probes to human and mouse a-tubulin, b-tubulin, and
18S RNA were synthesized with a random priming kit (Gibco BRL) from DNA
fragments obtained by PCR amplification of mouse or human cDNA and gel
purification of the DNA product. Ribonuclease protection assay (RPA) was
performed with 10 mg of total RNA by using the RiboQuant kit and the human
Stress-1 multiprobe template set (Pharmingen, San Diego, Calif.). Protected
RNA-RNA hybrids were resolved on a 5% denaturing polyacrylamide gel and
subjected to autoradiography. Quantitation was performed on a PhosphorIm-
ager (Molecular Dynamics, Sunnyvale, Calif.).
Comet assay. The comet assay was performed with RKO cells using a
CometAssay kit (Trevigen, Gaithersburg, Md.) according to the manufacturer’s
instructions. Briefly, at the end of the treatment, cells were placed on ice, washed
three times in ice-cold PBS, and counted. Approximately 250,000 cells were
mixed with low-melting-point agarose (1%, wt/vol) and were placed on specially
treated coverslips. Cells were lysed in a solution (2.5 M NaCl, 100 mM EDTA
[pH 10], 10 mM Tris base, 1% sodium lauryl sarcosinate, 1% Triton X-100) for
30 min. Following cell lysis, the slides were placed in alkali buffer (NaOH, pH .
13) for 60 min, rinsed in Tris-borate-EDTA (TBE) buffer, and electrophoresed
in 13 TBE buffer at 25 V for 20 min. The agarose was dehydrated by immersing
it in 100% ethanol for 10 min and air dried. The DNA was visualized using
SYBR-green dissolved in antifade solution and comets were analyzed on an
epifluorescence microscope by capturing images with a charge-coupled device-
cooled camera and analyzing individual comets with the Comet Analysis System
(Loats Associates, Westminster, Md). Tail moment (percentage of DNA in the
tail 3 length of migration) was automatically calculated after background cor-
rection for 75 comets in each experimental group. Results are reported as
absolute tail moment measurement 6 standard error of the mean (SEM).
RESULTS
Hypoxia induces p53 accumulation without increasing p21
protein levels. Activation of p53 protein by DNA damage is
followed by increased synthesis of downstream effector pro-
teins. The product of the p21–WAF-1–cip-1 gene (hereafter
referred to as p21) exhibits the most consistent upregulation by
p53 in response to DNA damage among various in vitro and in
vivo systems (11, 37). Although hypoxia has been previously
shown to induce p53 accumulation, it is not known whether
p53 accumulation is followed by upregulation of p21 levels. To
address this question we investigated the oxygen dependency
of p53 and p21 accumulation in the wt p53 cell line RKO,
which exhibits a p53-dependent upregulation of p21 after in-
frared (IR) treatment. Lowering oxygen levels from 20% to
0.02% by serial evacuations increased p53 protein levels (Fig.
1A). This increase was evident at O2 concentrations of 0.2%.
However, none of the decreased oxygen levels resulted in in-
creased p21 protein levels. In the human lymphocyte cell line
GM2184, both IR treatment and hypoxia caused an increase
in p53 levels of comparable magnitudes (Fig. 1B). However,
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while IR treatment of cells increased p21 levels, hypoxia de-
creased p21 levels. The same difference in the regulation of
p21 levels by IR treatment and hypoxia was found in RKO and
MCF-7 cells (Fig. 1C and D). Again, IR but not hypoxia in-
creased p21 levels. These results demonstrate that the inability
of hypoxia-induced p53 to induce p21 accumulation is not cell
line specific but occurs in cell lines of different lineage.
Hypoxia downregulates Mdm-2 protein levels. Another im-
portant p53-regulated effector is the product of the Mdm-2
oncogene. This transcriptional target of p53 participates in an
autoregulatory feedback loop that regulates p53 levels by bind-
ing to the N terminus of p53, inhibiting its transactivation
properties, and promoting its proteolytic degradation (20, 25,
33). In cells treated with hypoxia, Mdm-2 levels were markedly
repressed at 4 h and remained repressed up to 26 h under
hypoxia, while IR treatment induced a substantial increase in
Mdm-2 levels (Fig. 2A). The decrease in Mdm-2 levels was not
accompanied by a decrease in Mdm-2 mRNA levels (Fig. 2B),
indicating that the decrease in Mdm-2 levels by hypoxia is due
to a posttranscriptional mechanism. This decrease in Mdm-2
protein levels observed under hypoxia also suggests a likely
mechanism for the increased accumulation of p53 by hypoxia
(see Discussion).
p53 induced by hypoxia fails to induce transactivation of
endogenous downstream effectors. Since hypoxia failed to in-
crease p21 protein levels following p53 induction, we examined
the ability of hypoxia-induced p53 to upregulate transcription
of downstream effector genes. To address this question, we
assayed for the levels of various mRNAs of known downstream
p53 effectors after hypoxia or IR treatments. Such effectors
include the cyclin-cdk inhibitor p21, the proapoptotic protein
Bax, and the product of the growth arrest and DNA damage-
inducible gene GADD-45. These effector genes have p53-re-
sponsive elements in their promoter regions and are induced in
a p53-dependent manner following treatment with IR in a wide
variety of cell lines and tissues (11, 23, 30, 31). To assay the
levels of these products, we employed a multiribonuclease as-
say that allows the simultaneous detection of these mRNAs as
well as the mRNA levels of housekeeping genes as an internal
control in a single reaction.
wt p53 MCF-7 cells were irradiated or exposed for different
durations to hypoxia before protein and total RNA extraction.
FIG. 1. Hypoxia induces p53 accumulation but uncouples it from p21 accumulation. (A) Western blot analysis of p53 and p21 levels from RKO
exposed to different levels of hypoxia for 6 h or following 5 h of reoxygenation after hypoxia treatment. (B) Western blot analysis of p53 and p21
protein levels in GM2184B lymphoblasts with wt p53 following treatment with 6 Gy of IR or hypoxia for the indicated times. Also shown are
western blot analyses of p21 levels in RKO cells (C) and in MCF-7 cells (D) after treatment with 6 Gy of IR or with hypoxia for the indicated times.
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Induction of p53 occurred 8 h following hypoxia and reached
levels comparable to those obtained 3 h after treatment with
IR (Fig. 3A). However, hypoxia-induced p53 failed to increase
the mRNA levels of the p21, GADD-45, or Bax genes (Fig.
3B). From the mRNAs assayed in this set, only the mRNA of
the c-fos proto-oncogene increased under hypoxia, confirming
previous observations that hypoxia is an inducer of this imme-
diate-early gene (34). No change in p53 mRNA levels was
observed under hypoxia, indicating that as with IR, accumula-
tion of p53 protein by hypoxia is due to posttranscriptional
mechanisms. These results indicate that hypoxia does not in-
duce the transactivation of the same endogenous downstream
effectors of p53 that DNA damage induces. Similar results
were obtained in normal cervical epithelial cells, indicating
that the lack of transactivation by hypoxia-induced p53 is not
restricted to the transformed cell phenotype (Denko et al.,
unpublished results).
A DNA damage-inducible signal activates p53 transactiva-
tion under hypoxia. The lack of significant transactivation by
hypoxia-inducible p53 could be explained by the following hy-
potheses: (i) hypoxia downregulates or inhibits the interaction
of p53 with an accessory factor required for p53 transactiva-
tion, (ii) hypoxia-induced p53 or an accessory factor lacks a
modification which is present in DNA damage-induced cells
and which is necessary for transactivation, or (iii) both i and ii.
To distinguish between these possibilities, we examined the
transactivation properties of p53 in MCF-7 and RKO cells
treated with IR or hypoxia or treated with IR while exposed to
hypoxia. In MCF-7 cells, IR caused a significant dose-depen-
dent induction of GADD-45, p21, and Bax mRNA levels (Fig.
4). Note that based on the levels of L32 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNAs, lane 2 is un-
derloaded compared to control (lane 1) and the other lanes, by
a factor of 2.2 Treatment with hypoxia for 9 h failed to increase
GADD-45 or Bax levels, and increased p21 levels only 2- to
3-fold compared to 6- to 10-fold induction by 10 Gy of IR.
However, in cells treated with IR while under hypoxia, a sub-
stantial increase in the levels of these same mRNAs was ob-
served. Similar results to those found with MCF-7 cells were
obtained in RKO cells, although the increases in p21 and Bax
mRNA levels after combined hypoxia and IR treatments were
less pronounced than those observed in MCF-7 cells (Fig. 4).
This result suggests that hypoxia induces the accumulation of
transcriptionally latent p53 that upon DNA damage becomes
transcriptionally active. These results support the hypothesis
that lack of p53-dependent transactivation is due not to a
dominant, hypoxia-repressible event but rather to a lack of
modification(s) of p53 and/or of accessory protein(s), which is
induced by DNA damage.
Hypoxia induces nuclear accumulation of p53. One mecha-
nism that could explain the lack of p53-dependent transactiva-
tion of endogenous effector gene products under hypoxia is the
nuclear exclusion of hypoxia-induced p53. This possibility is
even more likely since the recent report by Ashcroft et al. (3)
that p53 stabilized by hypoxia-mimicking agents like deferox-
amine (DFO) was excluded from the nucleus. Although it was
previously shown that hypoxia induced nuclear accumulation
of p53 in untransformed human fibroblasts (15), it is still pos-
sible that in transformed cell lines like RKO, nuclear accumu-
lation or transport of hypoxia-induced p53 is compromised. To
address this question, we exposed RKO cells to hypoxia and
subjected them to immunocytochemistry using the DO-1
monoclonal antibody. Under normoxia, a very low level of p53
immunoreactivity was present in these cells (Fig. 5d). After
12 h of hypoxia, a strong p53 signal that localized to the cell
nuclei was evident (Fig. 5 f and h). These results indicate that
as was the case in untransformed human fibroblasts, hypoxia-
induced p53 accumulates in the nuclei of transformed cells and
suggest that the mechanism of induction of p53 levels by DFO
and physiological hypoxia are different.
Hypoxia induces p53-dependent transrepression. While p53
has been demonstrated to act as a transcriptional activator in
response to DNA damage, it can also repress transcription of
several downstream genes (1, 35–37, 41). Therefore, we exam-
ined the effect of hypoxia on the regulation of expression of
genes that have been shown to be repressed in a p53-depen-
dent manner. The mRNA for b-tubulin is repressed by p53
(35). To investigate whether the repression of b-tubulin is p53
dependent, we examined the effects of hypoxia on expression
of b-tubulin mRNA in the p53-null cell line H1299, which was
stably transfected with a p53-inducible gene construct under
the control of a tetracycline-regulated promoter (Fig. 6A). A
relatively low dose of doxycycline (200 ng/ml) was used to
moderately induce p53 in these experiments. Under these con-
ditions, we have found that p53 protein levels increase without
FIG. 2. IR but not hypoxia induces Mdm-2 protein and mRNA
accumulation. (A) Time course of the regulation of Mdm-2 levels in
cell extracts prepared at the indicated times under hypoxia or 3 h
following treatment with 6 Gy of IR. (B) Northern blot analysis of
Mdm-2 mRNA levels following treatment with hypoxia or 6 Gy of IR.
Hybridization to 18S rRNA was used as a loading control (Con).
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any substantial induction of apoptosis compared to uninduced
cells (data not shown). When H1299 cells were exposed to
hypoxia in the presence of doxycycline, the levels of b-tubulin
mRNA decreased to 38% of control levels. This decrease was
p53 dependent, as in the absence of the p53-inducible gene
hypoxia and doxycycline caused only a 6% decrease (Fig. 6B).
Another gene whose expression is repressed in a p53-depen-
dent manner is a-tubulin. mRNA levels of this gene decrease
in response to p53 induction that leads to growth arrest (36), or
to apoptosis (37). We assayed for changes in a-tubulin mRNA
levels in p531/1 and p532/2 MEFs after treatment with hyp-
oxia and UV. Hypoxia decreased a-tubulin mRNA levels to 22
and 25% of control levels after 8 and 16 h of treatment in the
p531/1 MEFs (Fig. 6C). UV treatment also caused a signifi-
cant decrease in a-tubulin levels. In p532/2 cells, however,
a-tubulin mRNA levels decreased only slightly in response to
hypoxia (85% at 6 h and 96% at 12 h) and moderately in
response to UV (67% at 3 h and 58% at 6 h). These results
indicate that while p53-dependent transactivation is absent in
cells exposed to hypoxia, p53 transrepression is still present.
Hypoxia fails to induce acetylation of Lys382 but induces
phosphorylation of Ser15. Activation of p53-dependent tran-
scriptional activity by DNA-damaging agents has been associ-
ated with specific posttranscriptional modifications of the pro-
tein. The transcriptional coactivator p300 has been shown to
interact with p53 and induce acetylation of its C terminus, at
Lys320 and Lys382 (18, 42). Furthermore, acetylation of p53 is
proposed to unmask the DNA binding domain of p53 and to
increase its transactivation ability. We investigated the effects
of hypoxia and IR on p53 acetylation using a rabbit polyclonal
antibody that recognizes p53 acetylated at Lys382. RKO cells
treated with hypoxia, IR, and the proteasome inhibitor ALLN
were lysed, and extracts were subjected to immunoblotting
using this antibody. ALLN induces accumulation of p53 pro-
tein by inhibiting its proteolytic degradation and does not in-
duce p53-dependent transactivation (Fig. 4). As seen in Fig.
7A, only IR caused a significant increase in p53 protein acet-
ylation, while 10 or 20 h of hypoxia did not result in an increase
in p53 acetylation at this site. ALLN also failed to induce this
modification.
In contrast, hypoxia exhibited an ability similar to that of IR
in stimulating phosphorylation of Ser15 (Fig. 7B). Human p53
is phosphorylated on at least two sites near the N terminus in
response to DNA damage: at Ser15 and Ser20 (8, 29, 45, 46,
48). Phosphorylation on Ser15 has been shown to decrease the
affinity of Mdm-2 for binding at the N terminus of the protein
(44). Treatment of RKO cells with hypoxia for 20 h induced
robust phosphorylation on Ser15 as determined by immuno-
blotting with a polyclonal antibody specific for phosphorylated
Ser15. IR also caused Ser15 phosphorylation 3 h after treat-
ment, while treatment with ALLN, a calpain I inhibitor that
induces p53 accumulation by decreasing its proteolytic degra-
FIG. 3. Hypoxia-induced p53 fails to transactivate endogenous ef-
fector gene mRNAs. MCF-7 cells were treated with hypoxia or with 6
Gy of IR, and at the times indicated whole-cell lysates and total RNA
was prepared. (A) Western blot analysis of p53 levels following treat-
ment of MCF-7 cells. (B) Multi-RPAs of mRNA levels of various p53
effectors and other genes involved in cellular stress and apoptotic
responses. RPAs were performed in MCF-7 cells using RNA probes
synthesized from a set containing various stress-induced genes (hStress
set). Probes that are complementary to two housekeeping genes (ribo-
somal protein L32 and GAPDH) serve as normalization controls
(Con).
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dation (46), did not result in Ser15 phosphorylation. When the
same immunoblot was stripped and reprobed with the DO-1
monoclonal antibody that recognizes wt p53 protein, a signif-
icant induction of p53 protein levels was observed in cells
treated with ALLN, IR, and hypoxia, compared to untreated
control cells. The phosphorylation of p53 on Ser15 was in-
duced as early as 4 h of hypoxia and was present at comparable
levels after 20 h of continuous exposure to hypoxia (Koumenis
et al., unpublished observations). Therefore, phosphorylation
of p53 on Ser15 is similar for both DNA damage and hypoxia.
Hypoxia fails to induce a p53-p300 interaction but promotes
a strong interaction between p53 and the corepressor mSin3A.
The lack of p53-dependent transactivation and acetylation of
p53 on Lys382 and the induction of p53-dependent transre-
pression by p53 under hypoxia suggest that hypoxia must in-
fluence the interaction of p53 with transcriptional accessory
proteins in a unique manner. To further elucidate the mecha-
nism of selective regulation of p53 function by hypoxia, we
examined the interactions between p53 and transcriptional co-
activators and corepressors. The transcriptional coactivator
FIG. 4. Irradiation of MCF7 and RKO cells under hypoxia induces p53-dependent transactivation. Cells were grown in normoxic conditions
(lanes 1 to 3, MCF-7, and lanes 1, 2, and 5, RKO) or exposed to hypoxia (lanes 4 to 6, MCF-7, and lanes 3 and 4, RKO). Cells in lanes 2, 3, 5,
and 6 (MCF-7) and lanes 2 and 4 (RKO) received 3 or 10 Gy of IR, as indicated, 3 h before cell lysis. Cells in lane 5 (RKO) were treated with
20 mM ALLN for 3 h before cell lysis. Following cell lysis, total RNA was isolated and RPAs were performed as described in Materials and
Methods.
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FIG. 5. Hypoxia-induced p53 is mainly localized to the nucleus. RKO cells were grown under normoxia (a to d), or exposed to hypoxia (e to
h). Nuclei were visualized with DAPI (49,69-diamidino-2-phenylindole) counterstaining (a, c, e, and g), while p53 was visualized using the DO-1
monoclonal antibody and a fluorescein-conjugated mouse secondary antibody (d, f, and h). Panel b depicts fluorescence due to binding of the
secondary antibody alone. Images in panels g and h were taken using a higher magnification objective (360) than the other panels (320).
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p300 has been shown to interact with a number of transcrip-
tional activators and enhancers, including p53, and its function
has been demonstrated to be indispensable for p53-dependent
transactivation (4, 18, 27, 42). The transcriptional corepressor
mSin3A, a member of the NCoR transcriptional repressor
complex, is utilized by transcriptional repressors like the Mad-
Max complex and nuclear hormone receptors and has recently
been shown to interact strongly with p53 (36). mSin3A also
interacts with histone deacetylases (HDACs), which promote
deacetylation of core histones at the promoter region and
induce transcriptional repression of specific genes (19).
The interaction between p53 and p300 or p53 and mSin3A
was examined in RKO cells treated with hypoxia, ALLN, or
IR. Accumulation of p53 protein was strongly induced in these
FIG. 6. Hypoxia induces p53-dependent transrepression. (A) Doxycycline (200 ng/ml) induces p53 expression in H1299 cells transfected with
a tet-inducible construct (clone 30) under normoxic and hypoxic conditions. The slight increase in p53 levels under hypoxia in the absence of
doxycycline is probably due to stabilization of residual p53 expressed due to the “leakiness” of the construct. (B) Northern analysis of b-tubulin
(b-tubul.) mRNA levels in an H1299 clone expressing a tet-inducible p53 construct and the parental clone transfected with empty vector. Cells were
treated with hypoxia, doxycycline, or doxycycline for 2 h followed by treatment with hypoxia. In this cell line, hybridization with the b-tubulin probe
results in two signals, probably because of alternative splicing of the b-tubulin. At the bottom, a methylene blue-stained nitrocellulose membrane,
indicating levels of 18S and 28S RNA is shown. (C) Northern blot analysis of the p53-transrepressed gene coding for a-tubulin after treatment of
p531/1 and p532/2 MEFs with hypoxia or with 10 J of UV radiation/m2. Hybridization to 18S rRNA was used as a control. This is a light
PhosphorImager scan that better represents the repression levels of a-tubulin. Values represent relative b-tubulin levels.
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cells by hypoxia, ALLN, and IR in a dose-dependent manner
(Fig. 8A). In extracts immunoprecipitated with an anti-p300
polyclonal antibody, p53 was present only in cells treated with
IR, with maximal levels occurring at 8 h post-IR treatment. In
contrast, in immunoprecipitates using an anti-mSin3A anti-
body, p53 was detected in cells treated with both hypoxia and
IR and to a lesser extent in cells treated with ALLN. The
strong interaction between p53 and mSin3A under hypoxic
conditions was time dependent and followed kinetics similar to
those of p53 induction. More significantly, higher levels of p53
were coimmunoprecipitated with mSin3A after 20 h of hypoxia
compared to the levels following treatment with ALLN, sug-
gesting that hypoxia induces a stress-specific modification that
leads to a strong interaction between p53 and mSin3A. No
change in the levels of p300 or mSin3A was observed following
treatments with hypoxia (Koumenis et al., unpublished data).
Since DNA damage is able to induce transactivation by
hypoxia-inducible, transcriptionally latent p53, we hypothe-
sized that DNA damage should be able to induce an interac-
tion between hypoxia-induced p53 and p300. We treated RKO
cells with doxorubicin, hypoxia, or a combination of both treat-
ments (Fig. 8B). Doxorubicin was used as the DNA-damaging
agent because we found that it induces higher levels of p53
accumulation and a stronger interaction between p53 and
p300. Both doxorubicin and hypoxia induced p53 accumula-
tion. The combination of the two treatments induced p53 ac-
cumulation that was no greater than the induction found by
doxorubicin or hypoxia alone. When lysates were immunopre-
cipitated with an anti-p300 antibody, p53 was present in the
extracts treated with doxorubicin but not with hypoxia. How-
ever, in cells treated with both doxorubicin and hypoxia, the
anti-p300 antibody was able to coimmunoprecipitate p53, in-
dicating that DNA damage induced an interaction between
p53 and p300 even under hypoxia. The lower levels of p53 in
this lane compared to those in extracts treated with doxorubi-
cin alone may reflect the difference in DNA damage induced
by doxorubicin under oxic versus hypoxic conditions as de-
tected by the comet assay (Fig. 8B). This assay measures DNA
damage in the genome through an increase in the electro-
phoretic mobility of nuclear DNA in an electrofield (12). The
increase in DNA mobility (seen as migrating DNA comet) is a
direct measure of the extent of total DNA damage (single- and
double-strand breaks). Hypoxia itself did not induce any mea-
surable DNA damage and reduced the net damage induced by
doxorubicin after a 12-h exposure.
The histone deacetylase inhibitor TSA reduces hypoxia-in-
duced apoptosis and p53-dependent transrepression. The p53-
mSin3A interaction under hypoxia suggests that transcriptional
repression mediated by this interaction may be important for
p53-induced apoptosis by this stress. To investigate this possi-
bility, we tested the effects of the HDAC inhibitor trichostatin
A (TSA) on p53-dependent apoptosis following treatments
with IR and hypoxia. TSA is an inhibitor of HDAC activity and
has been shown to inhibit transcription by several transcrip-
tional repressors, including p53 (24, 36, 54).
To test the effects of TSA on hypoxia- and IR-induced ap-
optosis, cells from tet-inducible H1299 cells were treated with
TSA alone, doxycycline, or TSA followed by doxycycline, and
cells with apoptotic morphology were visualized with Hoechst
33342 and propidium iodide staining and counted. As shown in
Fig. 9A, TSA did not cause significant changes in apoptotic
levels in cells under normoxic or hypoxic conditions or treated
with IR. Addition of doxycycline prior to treatment induced a
substantial increase in the apoptotic levels induced by hypoxia
or IR. The level of apoptosis induced by hypoxia was reduced
by TSA to the level of Dox treatment alone, suggesting that a
trichostatin-sensitive transcriptional repression pathway medi-
ates almost all p53-dependent apoptosis under hypoxia. In
contrast, only 40% of radiation-induced apoptosis was inhib-
ited by trichostatin, consistent with our data demonstrating the
interactions of p53 with both transcriptional activation and
repression pathways following IR treatments.
To test whether the reduction of apoptosis by TSA corre-
lated with a reduction in transcriptional repression, we assayed
the levels of a-tubulin mRNA (Fig. 9B). p53 was induced by
the addition of doxycycline, and RKO cells were treated in the
same manner as described above, but cells were lysed at earlier
time points to avoid effects due to apoptosis. Cells treated with
IR were lysed at 6 h following treatments, while cells treated
with hypoxia were lysed at 12 h after the onset of hypoxia. We
found that pretreatment with TSA did not alter the mRNA
levels of a-tubulin in untreated cells or cells treated with IR
or hypoxia (lanes 4 to 6, respectively). In contrast, pretreat-
ment with doxycycline caused a modest decrease of a-tubulin
mRNA levels in untreated cells (lane 7) and cells treated with
IR (lane 8), and a substantially bigger decrease in cells exposed
FIG. 7. Differences in p53 modifications induced by IR and hyp-
oxia. (A) IR but not hypoxia induces acetylation of Lys382. RKO cells
were treated with hypoxia, 6 Gy of IR, or 20 mM ALLN for the times
indicated. Immunoblotting was performed with a rabbit polyclonal
antibody raised against Lys382. (B) Both IR and hypoxia induce Ser15
phosphorylation of p53. Treatment times are indicated. The top panel
shows an immunoblot using a rabbit polyclonal that recognizes p53
phosphorylated at Ser15. The bottom panel shows the same immuno-
blot after being stripped and reprobed with the DO-1 monoclonal
antibody.
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to hypoxia (lane 9). When TSA was added 1 h prior to doxy-
cycline, no decrease in a-tubulin mRNA levels was seen in
IR-treated and hypoxia-treated cells compared to those in con-
trol cells. These results demonstrate that a strong correlation
exists between the ability of TSA to reverse hypoxia-induced
p53-dependent apoptosis and to inhibit p53-dependent trans-
repression.
DISCUSSION
The results described in this study demonstrate that hypoxia
is unique among stresses that modulate p53, as it induces p53
protein accumulation and transcriptional repression but not
the transcriptional induction of endogenous downstream effec-
tor genes. Furthermore, hypoxia is the first physiological stress
FIG. 8. Interactions of p53, p300, and mSin3A after hypoxia and ionizing radiation exposure. (A) Immunoprecipitation of mSin3a or p300 was
performed on extracts from cells treated with 3 Gy of IR (top) or hypoxia-ALLN (bottom) using polyclonal antibodies against the corresponding
proteins. One-tenth of the cell extract was loaded in a lane of each set to assay for p53 levels. The blot was probed with the DO-1 anti-p53
monoclonal antibody. (B) Immunoblot on cell lysate (top) and immunoprecipitation (IP) followed by immunoblotting (bottom) of p53 levels in
extracts of cells treated with doxorubicin (100 ng/ml) for 12 h, hypoxia for 12 and 24 h, or both doxorubicin (12 h) and hypoxia (24 h). In the third
case, doxorubicin was added during the last 12 h of hypoxia. The same anti-p300 polyclonal antibody (N-15) that was used in the top panel of B
was used here. The table at the bottom of the figure indicates the tail moment values from cells treated as described above as determined by the
Comet assay. Values are averages of 75 cells per treatment group and are reported along with SEMs for each group.
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that has been shown to lack a component of transactivation-
competent p53 for the induction of apoptosis.
One of the most consistently transactivated genes in re-
sponse to p53 induction is p21. Both p21 protein and mRNA
failed to increase in response to hypoxia in human and rodent
cells. The mRNA levels of other p53 effector genes, bax,
GADD-45, and APO-1-Fas also failed to increase in response
to hypoxia. Furthermore, we have shown that hypoxia not only
fails to activate another important effector of p53, Mdm-2, but
actually suppresses its protein levels. The lack of change in the
FIG. 9. (A) TSA inhibits p53-dependent apoptosis under hypoxia. H1299 cells transfected with a p53 expression vector under the control of the
tetracycline promoter were treated with IR or hypoxia. One group of cells did not receive any additional treatment (CON). TSA (25 nM) was added to
a second group 1 h prior to treatment. A third group was treated with doxycycline 2 h prior to treatment, while both TSA and doxycycline were added
to a fourth group prior to treatments. At the end of the treatment, cells with apoptotic morphology were visualized with Hoechst 3342 and phosphatidyl
inositol staining. The total number of cells and the number of apoptotic cells in four different fields in 60-mm-diameter dishes were counted and expressed
as the percentage of the total number of cells. Numbers represent the average of three independent experiments. Error bars represent SEM (B) TSA in-
hibits p53 transrepression under hypoxia. RKO cells were treated as described above, with the exception that cells were lysed 6 h after IR treatment and
12 h after hypoxia treatment. Northern blot analysis was performed on total RNA using a probe for human a-tubulin and 18S rRNA as described above.
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mRNA levels of Mdm-2 by hypoxia points to a posttranscrip-
tional mechanism for this decrease, like decreased mRNA
translation or enhanced protein ubiquination. The results pre-
sented here, which show a marked reduction of Mdm-2 levels
under hypoxia, provide a direct explanation for the observed
accumulation of p53 under hypoxic conditions. Taken to-
gether, the findings listed above indicate that the dissociation
between p53 accumulation and effector activation is not lim-
ited to one experimental system, nor does it apply to one
effector, but instead it reflects a conserved, stress-specific cel-
lular response.
The results from the experiments in which hypoxia is com-
bined with IR treatments strongly suggest that the lack of p53
transactivation under hypoxia is due to a specific posttransla-
tional modification(s) of p53 or an accessory protein which
requires DNA damage for induction. Phosphorylation of p53
at different sites, including Ser15 and Ser20, has been proposed
to induce the transcriptional activity of p53. However, at least
for phosphorylation at the Ser15 position of human p53, this
does not appear to be the case. Hypoxia was found to induce
significant phosphorylation of Ser15, indicating that modifica-
tion of this site alone is not sufficient for transcriptional activ-
ity. Furthermore, Ser15 phosphorylation does not appear to be
required for p53 protein accumulation under hypoxia, since we
have shown that the decrease in Mdm-2 levels under hypoxia is
most likely the mechanism of p53 accumulation under these
conditions (2).
Our immunocytochemistry experiments also rule out the
possibility that the lack of p53 transactivation is due to a failure
of hypoxia-induced p53 to accumulate in or be actively trans-
ported to the nucleus of RKO cells. These results extend our
previous findings using untransformed human fibroblasts but
also raise the interesting possibility that the mechanism for p53
accumulation by hypoxia is different from the one responsible
for induction by DFO or other hypoxia-mimicking agents.
While DFO and CoCl2 have been extensively used as a bio-
chemical surrogate of hypoxia, we have found that at the mo-
lecular level these stresses exhibit significant differences in
their profiles of induction of gene expression (Denko et al.,
unpublished observations). However, the finding by Ashcroft
et al. that p53 accumulated by a nongenotoxic stress is not
transcriptionally active is in agreement with our study (3).
The failure of p53 to become acetylated on Lys382 or to
associate with p300 under hypoxia indicates that the lack of
p300-p53 interaction and C-terminal acetylation may be re-
sponsible for the lack of p53-dependent transactivation of en-
dogenous effector genes under hypoxia. These findings also
underscore the requirement for C-terminal acetylation for p53-
dependent transactivation, irrespective of other modifications
that may occur at the N terminus. Other modifications like
phosphorylation of Ser20 or phosphorylations at the C termi-
nus in response to hypoxia treatments are currently being in-
vestigated.
The lack of association between p53 and p300 and acetyla-
tion of p53 at Lys382 under hypoxia is intriguing and may
provide a biochemical handle for understanding the relation-
ship between posttranslational modifications and activity of
p53. Alternatively, this lack of interaction between the two
proteins may be due to functional competition of p53 with
factors that limit the availability of p300. Interestingly, another
hypoxia-inducible factor, p35srj, has been reported to associate
with p300 and to inhibit Hif-1a activity (5). A similar mecha-
nism could be responsible for disrupting the association of p300
with p53. Still, our results with the combined hypoxia–DNA-
damaging treatments suggest that if any competitive inhibition
is responsible for lack of p53 transactivation under hypoxia,
then DNA damage must shift the dynamics of this competitive
inhibition towards a functional p53-p300 interaction.
It has been proposed that while p53 requires a functional
interaction with the transcriptional coactivator p300 and PCAF
(both proteins have histone acetylase and chromatin decon-
densation activities), p53-dependent transrepression may re-
quire interactions with proteins that possess deacetylase and
chromatin condensation properties, like HDACs (19, 36).
Murphy et al. have shown that p53 can coprecipitate not only
with mSin3A but also with HDAC, indicating that, by binding
to an as yet unidentified factor, p53 can recruit the HDAC
complex to the promoter. Using an immunoprecipitation-
PCR-based assay, they also demonstrated that this interaction
occurs at the promoters of the repressed genes like MAP4
(36). Our coimmunoprecipitation studies lend support to the
finding that p53 interacts with the histone deacetylase complex
in vivo through mSin3A. This interaction between p53 and
mSin3A is particularly strong under hypoxia.
What is the biological role of p53-dependent transrepression
under hypoxia? Murphy et al. have shown that overexpression
of the p53-repressed gene MAP4 delayed the onset of apopto-
FIG. 10. Model for the regulation of p53 function by genotoxic
stress (top) and hypoxia (bottom). See text for details.
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sis induced by activation of a temperature sensitive-p53 con-
struct (35). More recently, work from the same investigators
has shown that compromising transcriptional repression by
inhibiting histone deacetylase activity results in a dramatic
decrease in the levels of p53-dependent apoptosis (36). Here,
we also demonstrate that TSA decreases p53-dependent apo-
ptosis and transrepression of a-tubulin under hypoxic condi-
tions, to the levels of doxycycline-treated cells alone, indicating
that almost all of hypoxia-induced apoptosis occurs through
this trichostatin-sensitive pathway. This result is consistent
with our finding that hypoxia-inducible p53 only interacts with
transcriptional corepressors such as mSin3A and does not in-
teract with transcriptional cofactors such as p300. Further-
more, as DNA damage induces interactions between p53 and
both transcriptional coactivators and repressors, trichostatin
only reduced radiation-induced apoptosis by 40%. Thus, in the
case of activation of p53 by DNA damage, both transcriptional
activation and repression pathways appear to be involved, as
has been reported in the literature.
The results presented here describe a new paradigm for the
regulation of p53 function by a physiological stress. As de-
picted in our model (Fig. 10), DNA damage induces the mod-
ification of p53 and interaction with accessory proteins that
result in two pools of p53, one that possesses transactivation
potential and one that possesses transrepression potential.
Each pool of DNA damage-induced p53 is capable of inducing
apoptosis. In contrast, hypoxia-induced p53 primarily interacts
with transcriptional corepressors in signalling for apoptosis.
Although a variety of genes exist that are transcriptionally
repressed by p53, the identification of that gene(s) that mod-
ulates the critical effectors of apoptosis such as APAF-1 and
caspase 9 (47) in a p53-dependent manner will be the next
major contribution to understanding tumor suppression.
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